Advertisement
New Zealand markets open in 9 hours 23 minutes
  • NZX 50

    12,123.14
    -11.83 (-0.10%)
     
  • NZD/USD

    0.6086
    -0.0034 (-0.56%)
     
  • ALL ORDS

    8,262.40
    +56.30 (+0.69%)
     
  • OIL

    82.01
    -0.20 (-0.24%)
     
  • GOLD

    2,421.00
    +0.30 (+0.01%)
     

Stryker's (SYK) LIFEPAK 35 to Offer Advanced Monitoring System

Stryker Corporation SYK recently announced the launch of its latest device in the market, offering advanced technology, the LIFEPAK 35 monitor/defibrillator. The device is constructed on a user-friendly and modern platform to improve patient care.

LIFEPAK 35 is likely to enable more efficient workflow and provide advanced clinical solutions to emergency responders and healthcare professionals. This device is likely to provide life-saving teams real-time access to vital patient data, thus meeting their needs and improving patient care.

Price Performance

For the past six months, SYK shares have rallied 17.4% compared with the industry’s rise of 8.4%. The S&P 500 increased 16% in the same time frame.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

More on LIFEPAK 35

LIFEPAK 35 is a clinically advanced device designed to promote improved cardiac care, enable clinical excellence and deliver in demanding situations. The device’s advanced clinical decision support features and a large, user-friendly touchscreen offer a personalized clinical experience that lessens cognitive load at demanding times.

ADVERTISEMENT

The use of cutting-edge technology by emergency responders and healthcare professionals can assist expedite operations in their demanding, fast-paced workplaces. With real-time access to vital patient data, the LIFEPAK 35 system supports life-saving teams' demands while improving patient care.

Other Devices From Stryker

Stryker boats a range of connected digital solutions that aim to provide better patient care and aid in improving workflow.

Stryker’s 1688 Advanced Imaging Modalities (AIM) 4K Platform, the first system to use the 4K fluorescence technology managed by the Connected OR Hub, provides healthcare professionals seamless connectivity to images, data, and settings you need. Surgical teams are able to witness greater detail than ever with superior image clarity, more accurate color reproduction, and enhanced light quality.

The Blueprint 3D Planning and Mixed Reality system from Stryker aids surgeons to better understand glenoid, humeral and soft tissue deformities while learning about patients' pathology, anticipating challenges and evaluating the range of implant types that could be used. The system permits the use of 3D images and guidance widgets on patients and in the surgeon's line of sight to guide surgeons and their tools without interfering with regular workflow.

Industry Prospects

Per a report by Coherent Market Insights, the global emergency room triage market was estimated to be $3.1 billion in 2023 and is anticipated to exceed $6.27 billion by 2030 at a growth rate of 10.6%.

The market is likely to be driven by the rising incidence of trauma injuries and medical emergencies as these increase patient visits to emergency rooms. A growing geriatric population prone to chronic illnesses is likely to further boost demand.

Given the market potential, Stryker’s LIKEPAK 35 device is likely to boost the company’s business and generate additional revenues.

Notable Developments

In May 2024, Stryker announced the successful completion of the first European surgeries using the Infinity Total Ankle System with Adaptis and Everlast technology. Infinity with Adaptis builds on the legacy of the original Infinity Total Ankle, with a decade of clinical use.

In February, Stryker announced the successful completion of the first shoulder arthroplasty surgeries using Blueprint Mixed Reality (MR) Guidance in Europe. The Blueprint MR Guidance System allows surgeons and their instruments to be guided by 3D images and guidance widgets, which can be displayed on the patient and in the surgeon’s line of sight without disrupting normal workflow.

Stryker Corporation Price

Stryker Corporation Price
Stryker Corporation Price

Stryker Corporation price | Stryker Corporation Quote

Zacks Rank & Stocks to Consider

SYK carries a Zacks Rank #3 (Hold) at present.

Some better-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. ALGN, Ecolab ECL and Boston Scientific Corporation BSX.

Align Technology, currently carrying a Zacks Rank of 2 (Buy), reported first-quarter 2024 adjusted earnings per share (EPS) of $2.14, which beat the Zacks Consensus Estimate by 8.1%. Revenues of $997.4 million outpaced the consensus mark by 2.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Align Technology has a long-term estimated growth rate of 6.9%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 5.9%.

Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%.

Ecolab’s shares have rallied 33.8% against the industry’s 9.3% decline in the past year.

Boston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. It currently carries a Zacks Rank #2.

Boston Scientific has a long-term estimated growth rate of 12.5%. BSX’s earnings surpassed estimates in the trailing four quarters, the average surprise being 7.5%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Boston Scientific Corporation (BSX) : Free Stock Analysis Report

Ecolab Inc. (ECL) : Free Stock Analysis Report

Stryker Corporation (SYK) : Free Stock Analysis Report

Align Technology, Inc. (ALGN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research